Updated interim results from CLASSICAL-Lung, a phase Ib/II study of pepinemab in combination with avelumab (Bavencio) showed promise in patients with non-small cell lung cancer (NSCLC), according to a presentation at the American Association for Cancer Research (AACR) Virtual Annual Meeting I, held from April 27-28, 2020.1
The multi-center, open-label study is designed to evaluate the combination in 62 patients with advanced stage (IIIB/IV) NSCLC, including immunotherapy-naïve patients and those whose tumors progressed during or following chemotherapy.2 The data presented at AACR builds upon results previously presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November 2019.3
“Pepinemab is a humanized IGG4 antibody which binds to and blocks SEMA4D activity,” Jonathan W. Goldman, MD, from UCLA in Santa Monica, California, said in a poster…
